March 13, 2018 – Infraredx, a company that works in intravascular imaging for mapping coronary artery disease, today ...

At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully implantable within the chest experienced no malfunctions requiring replacement or removal of the device for blood clotting. Further, their risk of a stroke was halved compared with patients who received the established version of the pump that requires an abdominal location for the implant, according to research presented at the American College of Cardiology’s 67th Annual Scientific Session, March 10-12 in Orlando, Fla.

Philips announced health economic results from the DEFINE FLAIR clinical trial comparing cost-effectiveness between instant wave-free ratio (iFR) and fractional flow reserve (FFR) in the guidance of treatment of ischemic heart disease at the American College of Cardiology (ACC) annual meeting, March 10–12, 2018, in Orlando, Fla. The study found that an iFR-guided strategy offers a one-year average cost savings of $896 per patient compared to an FFR-guided strategy, while delivering consistent patient outcomes. iFR is a pressure-derived index unique to Philips, allowing a simplified hyperemia-free physiological assessment of coronary blockages.

Fysicon announced its acquisition by Canon Medical Systems Corporation. Linda Elberse, CEO of Fysicon, stated: "Being part of a major player as Canon Medical Systems Corporation gives us the opportunity to cover all parts of the world with our innovative systems. Now Canon Medical has completed the image by adding Fysicon’s new developed hemodynamic monitoring system “QMAPP”, the sophisticated device management system “DataLinQ” and the cloud based image distribution software “EVOCS" and last but not least Fysicon's knowledge of connectivity and workflow management. Canon Medical is a strong brand name and a leading supplier, which will help us take the next steps into strengthening and growing our footprint in the global market. Furthermore we will keep developing new technologies and exploring new areas in the medical field together with our new parent company. We are very proud to have joined forces!”

March 1, 2018 – Patients who were treated for breast cancer or lymphoma are more than three times at risk for developing ...